Eli Lilly: Reyvow Effective for Migraines in Phase 3 Trial
October 06 2020 - 7:38AM
Dow Jones News
By Matt Grossman
Eli Lilly & Co. said Tuesday that its Reyvow drug was shown
to be more effective compared with a placebo in easing pain from
migraine headaches in a Phase 3 study.
In the study, people who took 100 or 200 milligrams of Reyvow
were 3.8 times and 7.2 more likely, respectively, to have superior
pain freedom during at least two our of three migraine attacks
compared with people who took a placebo, Eli Lilly said.
The study also showed positive results in patients who had
previously taken a class of drugs called triptans for their
migraines but found them ineffective or intolerable, the company
said.
In the study, a group of 1,471 people received either the
smaller or larger dose of Reyvow or a placebo for each attack, the
company said. They recorded their pain levels in a diary as the
attacks proceeded.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
October 06, 2020 07:23 ET (11:23 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024
